Stanford phd candidate Calvin schmidt posts about investing opportunities in synthetic biology. Available for consulting on potential investments in this area.

Calvin Schmidt Synthetic Biology Index: July Update

Performance overview
Value at beginning of month: $101,388.15
Value at end of month: $101,916.25
Month over month change: +0.52%
Total CAGR: +3.34%

Related indices, monthly change
NASDAQ: +3.75%
IVV (iShares Core S&P 500): +2.27%
IBB (iShares NASDAQ Biotechnology Index): +3.02%
MXI (iShares Global Materials): +5.44%
VEGI (iShares MSCI Global Agriculture Producers): +3.48%
ICLN (iShares Clean Energy): +6.42%

Individual performances

The index continued to climb to new highs, reaching a record high during this month before dropping a few percent in the last week. Amyris turned it around, gaining over 20% this month. Horizon and Novozymes, the two most successful companies in the index, also continued to climb.

Changes made to index

None

Allocation as of July 28, 2017

Calvin Schmidt Synthetic Biology Index: August Update

Calvin Schmidt Synthetic Biology Index: June Update